uploads/2018/01/Chart-005-9.jpg

Eli Lilly’s 4Q17 Estimates: Elanco

By

Updated

Elanco

Elanco, Eli Lilly’s (LLY) Animal Health business, includes its food animal products and companion animal products. Elanco is expected to report growth in revenues during 4Q17, following strong sales and a favorable impact of foreign exchange during the quarter.

The chart above compares revenues for Elanco over the last few quarters. Elanco’s revenues include sales of animal products in the US as well as international markets.

Article continues below advertisement

Elanco’s revenues

Elanco includes the US sales of food animal products and companion animal products. Its revenues are expected to increase in 4Q17, following the increase in sales of companion animal products and the inclusion of Boehringer Ingelheim Vetmedica’s US vaccines. Elanco’s growth is expected to be partially offset by lower sales of food animal products during 4Q17.

Elanco’s international markets include the US sales of food animal products and companion animal products. Its revenues for the international animal health business are expected to increase during 4Q17, following the increase in sales from food animal products in all major markets outside the US. This increase is partially offset by lower companion animal product sales during the quarter.

Food and other products

Elanco’s food and other products are expected to report a decline in revenues during 4Q17, following lower sales of food animal products in the US markets. This decline is partially offset by its growth in the sales of food animal products in its international markets.

Companion animal products

Elanco’s companion animal products are expected to report growth in revenues during 4Q17, following the inclusion of US canine, feline, and rabies vaccines acquired from Boehringer Ingelheim’s Vetmedica.

The growth in revenues is expected to be driven by strong sales in the US markets, partially offset by lower sales of companion animal products from outside the US markets.

The SPDR S&P Pharmaceuticals ETF (XPH) holds 4.0% of its total investments in Eli Lilly (LLY), 4.2% in Pfizer (PFE), 4.6% in Allergan (AGN), and 4.5% in Merck & Co. (MRK).

Advertisement

More From Market Realist